{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-056848","form_type":"8-K","ticker":"CUE","cik":"0001645460","company_name":"Cue Biopharma, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.406054+00:00","generated_at":"2026-06-02T06:10:07.432116+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cue Biopharma reports Q1 2024 net loss $12.3M, cash $41M into Q1 2025","bullets":["Collaboration revenue $1.7M vs $0.2M YoY; net loss $0.25/share vs $0.29.","Cash and equivalents $41.0M at March 31, expected to fund operations into Q1 2025.","CUE-101 abstract accepted for oral presentation at ASCO 2024; FDA meeting on registrational path.","Preclinical CUE-401 (with Ono) and new CUE-500 series for autoimmune/inflammatory diseases.","R&D expenses $10.2M, G&A $4.2M; net loss $12.3M for the quarter."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-056848","json":"https://secwatch.observer/filing/0000950170-24-056848.json","markdown":"https://secwatch.observer/filing/0000950170-24-056848.md","text":"https://secwatch.observer/filing/0000950170-24-056848.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645460/000095017024056848/0000950170-24-056848-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645460/000095017024056848/cue-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:10:07.432116+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"94191d00dbff9ecb59c17f10d04c0e73b4876b4a","claim":"Cue Biopharma, Inc. reported first quarter 2024 results: revenue $1.7 million, net income Net loss $(12.3) million, EPS $(0.25) per share.","evidence_excerpt":"disease positions us well to potentially deliver value creation for our shareholders.” First Quarter 2024 Financial Results The Company reported collaboration revenue of $1.7 million and $0.2 million for the three months ended March 31, 2024 and 2023, respectively. The increase was due to revenue earned from our Collaboration and Option Agreement with Ono","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645460/000095017024056848/0000950170-24-056848-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2024"},{"label":"Revenue","value":"$1.7 million"},{"label":"Net income","value":"Net loss $(12.3) million"},{"label":"EPS","value":"$(0.25) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}